Loading
A phase 2 trial of Cemiplimab in non-small-cell lung cancer, run by Regeneron Pharmaceuticals, active and no longer recruiting.
A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1) is a phase 2 interventional study registered as NCT05557591 by Regeneron Pharmaceuticals, with 51 participants enrolled, started 2023-04-21 and due to reach its primary completion in 2028-01-26. Interventions recorded: BNT116, Cemiplimab. Conditions listed: Advanced Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Regeneron, PD-L1-high non-small-cell lung cancer without a driver mutation, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, PD-L1-high non-small-cell lung cancer without a driver mutation, Cemiplimab, Immune checkpoint inhibitors.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Cemiplimab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/